Having considered the impact of IDH mutations on splicing, we next examined if other mutations that have been implicated as glioma drivers or as clinically relevant markers for subgroup classification were associated with specific alternatively spliced genes. This evidence concerns the gene IDH2 and central nervous system cancer.